The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin
Open accessAbstract
Because of the role of thrombin and platelets in myocardial infarction and other pathological processes, identifying and blocking the receptors by which thrombin activates platelets has been an important goal. Three protease-activated receptors (PARs) for thrombin -- PAR1, PAR3, and PAR4 -- are now known. PAR1 functions in human platelets, and the recent observation that a PAR4-activating peptide activates human platelets suggests that PAR4 also acts in these cells. Whether PAR1 and PAR4 account for activation of human platelets by thrombin, or whether PAR3 or still other receptors contribute, is unknown. We have examined the roles of PAR1, PAR3, and PAR4 in platelets. PAR1 and PAR4 mRNA and protein were detected in human platelets. Activation of either receptor was sufficient to trigger platelet secretion and aggregation. Inhibition of PAR1 alone by antagonist, blocking antibody, or desensitization blocked platelet activation by 1 nM thrombin but only modestly attenuated platelet activation by 30 nM thrombin. Inhibition of PAR4 alone using a blocking antibody had little effect at either thrombin concentration. Strikingly, simultaneous inhibition of both PAR1 and PAR4 virtually ablated platelet secretion and aggregation, even at 30 nM thrombin. These observations suggest that PAR1 and PAR4 account for most, if not all, thrombin signaling in platelets and that antagonists that block these receptors might be useful antithrombotic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vu, T.-K. H., Hung, D. T., Wheaton, V. I., & Coughlin, S. R. (1991) · Cell · doi:10.1016/0092-8674(91)90261-v · Cited by 2,970
Self-citationAspirin Selectively Inhibits Prostaglandin Production in Human Platelets
SMITH, J. B., & WILLIS, A. L. (1971) · Nature New Biology · doi:10.1038/newbio231235a0 · Cited by 1,521
A dual thrombin receptor system for platelet activation
Kahn, M. L., Zheng, Y.-W., Huang, W., Bigornia, V., Zeng, D., Moff, S., Farese, R. V., Tam, C., & Coughlin, S. R. (1998) · Nature · doi:10.1038/29325 · Cited by 979
Self-citationAspirin as an Antiplatelet Drug
Wood, A. J. J., & Patrono, C. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301808 · Cited by 955
Protease-activated receptor 3 is a second thrombin receptor in humans
Ishihara, H., Connolly, A. J., Zeng, D., Kahn, M. L., Wu Zheng, Y., Timmons, C., Tram, T., & Coughlin, S. R. (1997) · Nature · doi:10.1038/386502a0 · Cited by 865
Self-citationCloning and characterization of human protease-activated receptor 4
Xu, W.-F., Andersen, H., Whitmore, T. E., Presnell, S. R., Yee, D. P., Ching, A., Gilbert, T., Davie, E. W., & Foster, D. C. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6642 · Cited by 817
Platelets in Biology and Pathology
Gordon, J. L. (1981) · Medical Entomology and Zoology · Cited by 638
Domains specifying thrombin–receptor interaction
Vu, T.-K. H., Wheaton, V. I., Hung, D. T., Charo, I., & Coughlin, S. R. (1991) · Nature · doi:10.1038/353674a0 · Cited by 552
Self-citationRole of the thrombin receptor in development and evidence for a second receptor
Connolly, A. J., Ishihara, H., Kahn, M. L., Farese, R. V., & Coughlin, S. R. (1996) · Nature · doi:10.1038/381516a0 · Cited by 505
Self-citationBalsano, F., Rizzon, P., Violi, F., Scrutinio, D., Cimminiello, C., Aguglia, F., Pasotti, C., & Rudelli, G. (1990) · Circulation · doi:10.1161/01.cir.82.1.17 · Cited by 386
Cited by
Thrombin signalling and protease-activated receptors
Coughlin, S. R. (2000) · Nature · doi:10.1038/35025229 · Cited by 2,482
Self-citationProteinase-activated Receptors
(2006) · Encyclopedic Reference of Molecular Pharmacology · doi:10.1007/3-540-29832-0_1335 · Cited by 1,137
Protease-Activated Receptors: Contribution to Physiology and Disease
OSSOVSKAYA, V. S., & BUNNETT, N. W. (2004) · Physiological Reviews · doi:10.1152/physrev.00028.2003 · Cited by 1,078
Protease‐activated receptors in hemostasis, thrombosis and vascular biology
COUGHLIN, S. R. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01377.x · Cited by 1,035
Self-citationTobacco smoking leads to extensive genome-wide changes in DNA methylation
Zeilinger, S., Kühnel, B., Klopp, N., Baurecht, H., Kleinschmidt, A., Gieger, C., Weidinger, S., Lattka, E., Adamski, J., Peters, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063812 · Cited by 824
“The F2RL3 protein is relevant for cardiovascular physiology and plays a role in platelet activation [40] and cell signaling [4].”
BackgroundAdhesion Mechanisms in Platelet Function
Ruggeri, Z. M., & Mendolicchio, G. L. (2007) · Circulation Research · doi:10.1161/01.res.0000267878.97021.ab · Cited by 755
The cytoprotective protein C pathway
Mosnier, L. O., Zlokovic, B. V., & Griffin, J. H. (2007) · Blood · doi:10.1182/blood-2006-09-003004 · Cited by 754
Activation of Platelet Function Through G Protein–Coupled Receptors
Offermanns, S. (2006) · Circulation Research · doi:10.1161/01.res.0000251742.71301.16 · Cited by 725
Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa
Camerer, E., Huang, W., & Coughlin, S. R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.10.5255 · Cited by 675
Self-citationProteinase-Activated Receptors
Macfarlane, S. R., Seatter, M. J., Kanke, T., Hunter, G. D., & Plevin, R. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01493-5 · Cited by 641
Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells
Palumbo, J. S., Kombrinck, K. W., Drew, A. F., Grimes, T. S., Kiser, J. H., Degen, J. L., & Bugge, T. H. (2000) · Blood · doi:10.1182/blood.v96.10.3302 · Cited by 605
Central role of the P2Y12 receptor in platelet activation
Dorsam, R. T., & Kunapuli, S. P. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420986 · Cited by 594
Cross Talk Pathways Between Coagulation and Inflammation
Foley, J. H., & Conway, E. M. (2016) · Circulation Research · doi:10.1161/circresaha.116.306853 · Cited by 589
How the protease thrombin talks to cells
Coughlin, S. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11023 · Cited by 576
Self-citationPAR3 is a cofactor for PAR4 activation by thrombin
Nakanishi-Matsui, M., Zheng, Y.-W., Sulciner, D. J., Weiss, E. J., Ludeman, M. J., & Coughlin, S. R. (2000) · Nature · doi:10.1038/35007085 · Cited by 557
Self-citationInfection and inflammation and the coagulation system
Levi, M. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00857-x · Cited by 517
Steinhoff, M., Buddenkotte, J., Shpacovitch, V., Rattenholl, A., Moormann, C., Vergnolle, N., Luger, T. A., & Hollenberg, M. D. (2005) · Endocrine Reviews · doi:10.1210/er.2003-0025 · Cited by 501
The Immunopathogenesis of Sepsis in Elderly Patients
Opal, S. M., Girard, T. D., & Ely, E. W. (2005) · Clinical Infectious Diseases · doi:10.1086/432007 · Cited by 460
International Union of Pharmacology. XXVIII. Proteinase-Activated Receptors
Hollenberg, M. D., & Compton, S. J. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.203 · Cited by 442
Foster, C. J., Prosser, D. M., Agans, J. M., Zhai, Y., Smith, M. D., Lachowicz, J. E., Zhang, F. L., Gustafson, E., Monsma, F. J., Wiekowski, M. T., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12242 · Cited by 415
Scientific and therapeutic advances in antiplatelet therapy
Bhatt, D. L., & Topol, E. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd985 · Cited by 407
Interplay between platelets and coagulation
Sang, Y., Roest, M., de Laat, B., de Groot, P. G., & Huskens, D. (2021) · Blood Reviews · doi:10.1016/j.blre.2020.100733 · Cited by 405
Thrombin and Platelet Activation
Brass, L. F. (2003) · Chest · doi:10.1378/chest.124.3_suppl.18s · Cited by 404
Signaling events underlying thrombus formation
Jackson, S. P., Nesbitt, W. S., & Kulkarni, S. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00267.x · Cited by 380
Heuberger, D. M., & Schuepbach, R. A. (2019) · Thrombosis Journal · doi:10.1186/s12959-019-0194-8 · Cited by 371
Structure, function and pathophysiology of protease activated receptors
Adams, M. N., Ramachandran, R., Yau, M.-K., Suen, J. Y., Fairlie, D. P., Hollenberg, M. D., & Hooper, J. D. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.003 · Cited by 370
Jurasz, P., Alonso‐Escolano, D., & Radomski, M. W. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706013 · Cited by 357
Clinical Aspects of Platelet Inhibitors and Thrombus Formation
Meadows, T. A., & Bhatt, D. L. (2007) · Circulation Research · doi:10.1161/01.res.0000264509.36234.51 · Cited by 351
Cathepsin G Activates Protease-activated Receptor-4 in Human Platelets
Sambrano, G. R., Huang, W., Faruqi, T., Mahrus, S., Craik, C., & Coughlin, S. R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.10.6819 · Cited by 345
Self-citationDeadly allies: the fatal interplay between platelets and metastasizing cancer cells
Erpenbeck, L., & Schön, M. P. (2010) · Blood · doi:10.1182/blood-2009-10-247296 · Cited by 345
Frelinger, A., Michelson, A., & Gremmel, T. (2016) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0035-1564835 · Cited by 345
Eto, M., Kozai, T., Cosentino, F., Joch, H., & Lüscher, T. F. (2002) · Circulation · doi:10.1161/01.cir.0000015465.73933.3b · Cited by 330
Targeting proteinase-activated receptors: therapeutic potential and challenges
Ramachandran, R., Noorbakhsh, F., DeFea, K., & Hollenberg, M. D. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3615 · Cited by 312
Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more
Ramachandran, R., & Hollenberg, M. D. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707507 · Cited by 305
Wan, E. S., Qiu, W., Baccarelli, A., Carey, V. J., Bacherman, H., Rennard, S. I., Agusti, A., Anderson, W., Lomas, D. A., & DeMeo, D. L. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds135 · Cited by 304
Thrombin Responses in Human Endothelial Cells
O'Brien, P. J., Prevost, N., Molino, M., Hollinger, M. K., Woolkalis, M. J., Woulfe, D. S., & Brass, L. F. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.18.13502 · Cited by 297
Protease-activated receptor 2 signaling in inflammation
Rothmeier, A. S., & Ruf, W. (2012) · Seminars in Immunopathology · doi:10.1007/s00281-011-0289-1 · Cited by 289
Protease-Activated Receptors in Cardiovascular Diseases
Leger, A. J., Covic, L., & Kuliopulos, A. (2006) · Circulation · doi:10.1161/circulationaha.105.574830 · Cited by 289
Ma, L., Perini, R., McKnight, W., Dicay, M., Klein, A., Hollenberg, M. D., & Wallace, J. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406682102 · Cited by 273
Özmen, L., Ekdahl, K. N., Elgue, G., Larsson, R., Korsgren, O., & Nilsson, B. (2002) · Diabetes · doi:10.2337/diabetes.51.6.1779 · Cited by 265
The protease-activated receptor-2 upregulates keratinocyte phagocytosis
Sharlow, E. R., Paine, C. S., Babiarz, L., Eisinger, M., Shapiro, S., & Seiberg, M. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.17.3093 · Cited by 150
Protease-activated receptors in health and disease
Peach, C. J., Edgington-Mitchell, L. E., Bunnett, N. W., & Schmidt, B. L. (2023) · Physiological Reviews · doi:10.1152/physrev.00044.2021 · Cited by 116
Mackenzie, A. P., Schatz, F., Krikun, G., Funai, E. F., Kadner, S., & Lockwood, C. J. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.08.003 · Cited by 95
Ryan, A. S., Keske, M. A., Hoffman, J. P., & Nelson, E. B. (2009) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31817fe2be · Cited by 72
Role of a JAK3-dependent biochemical signaling pathway in platelet activation and aggregation
Tibbles, H. E., Vassilev, A., Wendorf, H., Schonhoff, D., Zhu, D., Lorenz, D., Waurzyniak, B., Liu, X.-P., & Uckun, F. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011405200 · Cited by 51
Metadata
- Authors
- Kahn, M. L., Nakanishi-Matsui, M., Shapiro, M. J., Ishihara, H., & Coughlin, S. R.
- Venue
- Journal of Clinical Investigation
- Published
- 1999-03-15
- Volume
- 103
- Issue
- 6
- Pages
- 879-887
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2091112630
- Cited by
- 841
- References
- 29
- FWCI
- 19.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.